

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the "Stock Detailed Analysis Report" provided for **SUNPHARMA.NS** (generated 2026-02-14), here is the positional trade analysis.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily and Weekly candlestick charts (up to Feb 2026).
 - **Trend Indicators:** EMA (20, 50, 200), Supertrend, MACD.
 - **Volatility:** Bollinger Bands, ATR, Volatility Squeeze analysis.
 - **Momentum/Volume:** RSI, Volume MA, Accumulation/Distribution analysis.
 - **Fundamentals:** Revenue/EPS growth, ROE, and Analyst Ratings.
- **Data Missing:**
 - **Derivatives Data:** No Open Interest (OI) or Option Chain data to pinpoint max pain or institutional positioning.
 - **Sector Performance:** While **^CNXPHARMA** is mentioned, a direct comparative chart of the sector vs. the stock is limited to RS lines.
- **Confidence Level: High.** The report is comprehensive.
 - *Note:* There is a data conflict regarding the Supertrend. Page 10 and 11 indicate a **BUY** signal (Support ~1613), while the summary table on Page 22 lists a **SELL** signal. Based on the visual chart on Page 11 and current price action relative to the 200 EMA, I will prioritize the chart data (**Bullish/Neutral**) over the summary table.

Step 2: Analyze the Setup

- **Price Structure (Consolidation):** The stock is in a classic intermediate-term consolidation phase. After hitting highs near INR 1,900, it corrected and is now basing between INR 1,600 and INR 1,700.
- **EMA Cluster (Indecision):** The 20, 50, and 200 Daily EMAs are tightly bunched between INR 1,681 and INR 1,692 (Page 6). The price (INR 1,697.50) is currently hovering *inside* this cluster. This indicates a lack of immediate trend but suggests a breakout is imminent.
- **Volatility Squeeze:** Page 8 shows a Bollinger Band Width of 0.11 (very tight). Page 14 confirms multiple "BB Squeeze" signals. This is a high-probability setup indicating that the current low volatility will soon be followed by a violent expansion (big move).
- **Momentum:**
 - **MACD:** **Bullish** crossover (Page 13) with the histogram rising above zero, suggesting momentum is shifting to the upside.
 - **RSI:** Neutral at 53, rising from oversold levels. This allows plenty of room for upside before becoming overbought.
- **Fundamentals:** The company shows consistent growth (Page 3) and strong analyst consensus (Strong Buy, Target INR 1,963 on Page 25), providing a safety net for long positions.

Step 3: Formulate the Recommendation

Recommendation: NO (Wait for Confirmation)

Reasoning: While the setup is bullish in the long term, entering exactly at INR 1,697 is risky because the

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

price is still entangled in the EMA cluster and "No Control" candlesticks (Page 20) indicate indecision. As a risk-averse trader, you should wait for the price to clear the immediate resistance (the Upper Bollinger Band and the 1,720 psychological level) to confirm that the Volatility Squeeze is resolving to the upside.

Conditional Plan:

- **Condition to Buy: Daily Close above INR 1,725.**
 - *Why:* This clears the EMA cluster, the Supertrend resistance listed on Page 22, and the recent consolidation noise. It confirms the bulls have won the struggle at the 200 EMA.
- **Entry Price: INR 1,725 - INR 1,735** (Enter on the breakout or retest of this level).
- **Stop Loss: INR 1,640** (Hard Stop).
 - *Why:* This is below the 200 EMA (INR 1,686), the Middle Bollinger Band (INR 1,655), and the recent swing lows. If price closes below this, the squeeze has failed downward.
- **Take Profit: INR 1,880 - INR 1,950.**
 - *Why:* INR 1,880 tests the previous swing highs. INR 1,950 aligns with the analyst consensus target (Page 25) and psychological resistance near ATH. This offers an **8% - 13% upside**, fitting your criteria.

Candlestick Classification Analysis

Based on the **Candlestick Classification** report (Page 20) and the **Daily Chart** (Page 21), here is my analysis as a seasoned Price Action Trader.

1. Current Market State: "No Control" (Indecision)

- **Latest Classification: No Control (0)**
- **10-Day Trend Score: 0.30** (Neutral/Weak **Bullish**)

Interpretation: The market for Sun Pharma is currently in a state of **equilibrium and indecision**. After a period of volatility, the most recent price action has compressed. The "No Control" classification tells us that neither the bulls nor the bears have been able to close the day with conviction relative to the ATR (volatility).

Looking at the chart on Page 21, the last few candles are grey (No Control) or small-bodied. This indicates:*

Small Bodies: The distance between Open and Close is small (<0.5 ATR), signaling a lack of momentum.*

Wicks: The presence of wicks on both sides implies intraday battles where both breakout attempts (up) and breakdown attempts (down) failed.* **Volume:** The volume bars on these recent grey candles appear to be average or declining, failing to trigger the "Volume Multiplier" in the algorithm. This confirms a lack of institutional participation at this specific price level (~1700).

2. Price Action Context (The Story on the Chart)

To predict the next move, we must look at the sequence leading up to this indecision:

1. **The Drop (Seller Control):** In late January/early February (right side of the chart), we see a cluster of **Red Candles** (Seller Control / Seller Strong Control). These were large-bodied candles with higher volume, indicating strong institutional selling pressure that drove the price from ~1750 down to ~1580.
2. **The Bounce (Weak Buyer Control):** The stock found a temporary floor and bounced back to the current

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

~1700 level. However, notice the color of the candles during this rise. They are a mix of light green (Buyer Control) and grey (No Control). We lack the **Dark Green (Buyer Strong Control)** candles that would signify a "V-shaped" recovery or a true trend reversal.

- The Stall (Current):** The price has stalled at the 1700 resistance area. The "Recent Trend Score" of **0.30** reflects this. It is technically positive, but barely. A score of 0.30 is "noise." It suggests a weak retracement against a stronger downtrend.

3. Prediction: Which side is the future price likely to be?

Verdict: **Bearish Bias (Downside Risk)**

Reasoning based on the Classification Logic: The current "No Control" phase resembles a **Bearish Flag** or a consolidation pattern within a broader corrective move.

- The Logic:** The previous move (the drop) had high conviction (Seller Control). The current move (the bounce) has low conviction (No Control/Weak Buyer Control). In price action physics, when a strong force is met with a weak opposing force, the strong force usually resumes.
- The Trap:** The "No Control" candles at the top of this bounce suggest buyers are exhausted. They cannot push the price close to the highs of the day (Step 2 of the algorithm: Close Position).

What to watch for (The Trigger): * **Short Signal:** If the next 1-2 candles print a **Seller Control (-1)**

classification (closing near lows with increasing volume), the price is likely to revisit the recent lows of **1580**.*

Long Signal (Unlikely but possible): To turn bullish, we need a **Buyer Strong Control (+2)** candle to break the 1720 level. This requires a large body closing near the high with volume >1.3x average. Without that volume, any move up is likely a "fake-out."

Trader's Summary: The bulls are weak. The 10-day score of 0.30 is insufficient to sustain a trend. Expect the price to drift sideways or roll over to the downside.

News & Analyst Targets

Based on the latest available information for the week ending **February 14, 2026**, here is the stock research report for **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)**.

1) Latest News for SUNPHARMA This Week (Feb 8 - Feb 14, 2026)

- Strong Q3 FY26 Financial Performance:** Sun Pharma continues to ride the momentum of its Q3 earnings declared recently. The company reported a **16% YoY rise in consolidated net profit to INR 3,369 crore** and a **13.5% increase in revenue to INR 15,520 crore**. EBITDA margins expanded to **31.9%**.
- Dividend Declaration:** The board has declared an interim dividend of **INR 11 per share** for FY26.
- Acquisition Strategy Update (Feb 8):** Chairman Dilip Shanghvi clarified the company's M&A stance this week, stating they will maintain a "disciplined approach." The focus remains on **innovative medicines in the US** and smaller "tuck-in" deals in emerging markets, rather than aggressive expansion for the sake of size.
- Stock Trend:** The stock has gained approximately **7%** since the start of February, supported by the strong earnings and positive sentiment surrounding a new **India-US trade deal** which is expected to benefit Indian pharma exporters.
- Technical Breakout Signals:** As of Feb 11, technical analysts noted a shift in momentum. **MarketsMojo** upgraded the stock from 'Hold' to 'Buy', citing improved technical indicators and robust fundamentals.

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

2) Brokerage Upgrades & Downgrades

- **Upgrade to BUY (MarketsMojo):** On **February 11, 2026**, the stock was upgraded to a **BUY** rating (previously Hold). The rationale includes a "mildly bullish" technical trend shift and sustained financial performance.
- **BNP Paribas (Retained Outperform):** In a note dated **February 13, 2026**, BNP Paribas retained its 'Outperform' rating. They raised their FY26 operating margin estimates by 120 basis points following the Q3 margin beat.
- **General Consensus:** Most brokerages have maintained a positive stance post-Q3 results, driven by the growth in the Global Specialty business and strong domestic formulation sales.

3) Other News Impacting SUNPHARMA

- **US FDA & Quality Issues (Negative/Ongoing):**
 - **Product Recalls:** In late January 2026, Sun Pharma's US subsidiary initiated a Class III recall for over 26,000 bottles of generic dermatological medications (Clindamycin Phosphate and Fluocinolone Acetonide) due to "Failed Impurities/Degradation" specifications.
 - **Regulatory Status:** The **Halol facility** remains under scrutiny with an "Official Action Indicated" (OAI) status as of late 2025, which continues to restrict new approvals from this plant.
- **Sectoral Tailwinds:** A new **India-US trade deal** mentioned in market reports this week has improved sentiment for the entire Nifty Pharma index, with Sun Pharma being a key beneficiary due to its significant US revenue exposure (~30%).

4) Latest Analyst Price Targets (Feb 2026)

The following targets reflect the most recent updates from analysts following the Q3 FY26 results.

Brokerage / Analyst Firm	Rating	Price Target (INR)	Date of Report	Notes
BNP Paribas	Outperform (Buy)	INR 2,250	Feb 13, 2026	Raised margin estimates; cites strong specialty launch execution.
Rediff / Brokerage Consensus	Buy	INR 1,999	Feb 13, 2026	Consensus target cited in recent financial news reports.
Trendlyne Consensus	--	INR 1,926	Feb 14, 2026	Average of long-term targets from multiple analysts.
EquityPandit	Technical View	INR 1,805 - INR 1,880	Feb 06, 2026	Short-term resistance levels seen as immediate technical targets.

Disclaimer: This report is for informational purposes only and does not constitute financial advice. Please consult with a certified financial advisor before making investment decisions.


Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1697.50

Generated: 2026-02-14 10:10

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	12.21%	4.11%
Net Income	Yes	47.84%	5.85%
ROE	No	-32.32%	-32.32%
EPS	Yes	47.37%	16.76%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Emerging Leader
RS Score:	50.1/100
:	

== RS RATIOS ==:

1M RS:	1.021 [Leader]
3M RS:	0.990 [Neutral]
6M RS:	1.016 [Leader]
1Y RS:	0.964 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✓ Emerging RS:	1M (1.021) > 3M (0.990)
✓ Medium-term Lagging:	1Y=0.964 (≤ 1.0)
✗ Performance Improving:	Not improving

Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPBARMA
Classification: Emerging Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1681.68
EMA 50:	1692.17
EMA 200:	1686.21
Trend Status:	Short-term Downtrend
Golden Cross Date:	2025-11-14 00:00:00+05:30
Golden Cross Price:	1745.76


SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1697.50
Upper Band:	1751.19
Middle Band (SMA 20):	1655.08
Lower Band:	1558.98
%B:	0.7207
Band Width:	0.1161
Status:	Upper Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-12-30 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2026-01-20 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-21 00:00:00+05:30


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



SUNPHARMA.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1613.29
Signal Identified On:	2026-02-10


Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	3.53
Signal Line:	-7.59
Histogram:	11.12
Trend:	Bullish
Momentum:	Weakening
Signal:	None

SUNPHARMA.NS Price




SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.1161
ATR:	32.3465
Total Signals:	9
Signal 1:	BB Squeeze at 2025-12-15 00:00:00+05:30 (Price: 1785.50)
Signal 2:	BB Squeeze at 2025-12-16 00:00:00+05:30 (Price: 1769.80)
Signal 3:	BB Squeeze at 2025-12-17 00:00:00+05:30 (Price: 1781.33)
Signal 4:	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1716.85)
Signal 5:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1717.74)

SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	53.62
Current Volume:	1148165
Volume MA 20:	3194739
Bullish Divergences:	1
Bearish Divergences:	2
Bullish Div 1:	Date: 2025-06-04 00:00:00+05:30, Price: 1648.73
Bearish Div 1:	Date: 2024-04-01 00:00:00+05:30, Price: 1598.69
Bearish Div 2:	Date: 2025-07-30 00:00:00+05:30, Price: 1722.61

SUNPHARMA.NS RSI-Volume Divergence Analysis



SUNPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

38 Signals Detected

:

2025-12-29 [+]:

Selling Exhaustion (Bullish Div)

2026-01-08 [-]:

Distribution Day

2026-01-21 [-]:

Distribution Day



2026-01-29 [-]:

Distribution Day

2026-02-03 [-]:

Climax Volume (Churning)

SUNPHARMA.NS - Volume Analysis



SUNPHARMA.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **No Control**

Recent Trend Score (10-day avg): 0.30

:

Distribution:

No Control: 118

Buyer Control: 58

Seller Control: 49

Seller Strong Control: 3

SUNPHARMA.NS - Candlestick Classification



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1761.01	1697.5	2026-01-12
1 Day	DOWNTREND (Sell)	1715.95	1697.5	2025-12-18
15 Min	DOWNTREND (Sell)	1709.53	1699.1	2026-02-13

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bearish	Weakening	No Signal

SUNPHARMA.NS - 1 Week (Candlestick + EMAs)




SUNPHARMA.NS - 1 Day (Candlestick + EMAs)




SUNPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - SUNPHARMA_main



Trendlyne Snapshot - SUNPHARMA_forecaster



Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1963, revenue growth forecast of 10.5%, and profit growth estimate of 5.8% for FY26, based on top 38 analyst calls.

Sun Pharmaceutical FORECASTER - Analyst Estimates ^{NEW} ¹

[FORECASTER DASHBOARD](#) →

